Advertisement Covers CROI 2015


CROI 2015: The Future of Antiretroviral Treatment for Prevention (Video)

April 29, 2015

Andy Kaytes, on behalf of IFARA, spoke with Daniel Kuritzkes, M.D., David Wohl, M.D., and Kathleen Squires, M.D., about the future of antiretroviral therapy in HIV prevention. The strategy of using the same medication both for the treatment and prevention of a disease is also employed for malaria and other conditions. Only a few antiretroviral drugs have been studied for HIV prevention, notably tenofovir/emtricitabine (Truvada), but rates of protection have been very high. Another tenofovir prodrug, tenofovir alafenamide (TAF), affects the kidneys and bones less than tenofovir disoproxil fumarate and is equally effective in treating HIV. It is, however, unclear whether the U.S. Food and Drug Administration (FDA) will approve TAF for HIV prevention because the necessary studies comparing the two pro-drugs are "nearly impossible" to conduct, said Kuritzkes. Two exciting new developments in pre-exposure prophylaxis (PrEP) are a long-acting injectable form of tenofovir, as well as an insertable vaginal ring containing dapivirine. Squires pointed out the importance of "easy and cheap administration" of PrEP, because "the vast majority" of people affected by HIV live in resource-poor settings. A barrier to PrEP in the U.S., according to Wohl, is the reluctance of many primary care physicians to talk about sex with their patients. As a result, PrEP may not be prescribed, even if appropriate.

Watch the video to learn more:

About the panelists:

  • Daniel Kuritzkes, M.D., Brigham and Women's Hospital, Cambridge, Mass.
  • David Wohl, M.D., Division of Infectious Diseases, University of North Carolina.
  • Kathleen Squires, M.D., director of the Division of Infectious Diseases, Thomas Jefferson University Hospital, Philadelphia.

Barbara Jungwirth is a freelance writer and translator based in New York.

Follow Barbara on Twitter: @reliabletran.

Copyright © 2015 Remedy Health Media, LLC. All rights reserved.

This article was provided by TheBodyPRO. It is a part of the publication The 22nd Conference on Retroviruses and Opportunistic Infections (CROI 2015).

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.